Streamline Health CEO buys $1,008 in company stock

In a recent transaction, Benjamin Louis Stilwill, the President and CEO of Streamline Health Solutions Inc. (NASDAQ:STRM), has increased his stake in the company through the purchase of additional shares. The executive bought a total of 6,300 shares of common stock at a price of $0.16 per share, amounting to a total investment of $1,008.

This purchase was executed on September 20, 2024, and was reported in a filing with the Securities and Exchange Commission on September 24. According to the filing, these shares were acquired directly by Mr. Stilwill in an open market transaction, reflecting his ongoing commitment to the company. Following this transaction, Mr. Stilwill now directly owns a total of 611,576 shares in Streamline Health Solutions Inc.

Streamline Health Solutions, based in Alpharetta, Georgia, operates in the healthcare information technology sector and specializes in computer integrated systems design. The company's focus is on providing solutions to improve healthcare providers' efficiency and effectiveness.

The CEO's recent stock purchase is a move that may be of interest to current and potential investors, as it demonstrates confidence in the future of the company by one of its top executives. The transaction details indicate a straightforward increase in Mr. Stilwill's equity position in the company, without any complex equity swaps involved.

Investors looking to keep track of Streamline Health Solutions' financial movements can follow the stock under its trading symbol STRM on the NASDAQ exchange.



In other recent news, Streamline Health Solutions Inc. has reported a decrease in total revenue from $5.8 million to $4.5 million in the second quarter, compared to the same period last year. On a brighter note, the company has experienced a 21% growth in pro forma SaaS revenue for the first half of fiscal 2024, despite non-renewals totaling $2.8 million in SaaS Annual Contract Value (ACV). The booked SaaS ACV reached $13.6 million, with $10.7 million already implemented.

In another significant development, the company has approved a reverse stock split, with the exact ratio to be determined by the Board of Directors. This strategic move, supported by approximately 81% of the outstanding shares of common stock, is aimed at adjusting the number of shares in circulation.

Looking ahead, Streamline Health Solutions anticipates a revenue decline of $300,000 in Q3 2024 but expects recovery to $4.5 million in Q4. For fiscal 2025, a significant revenue growth along with improved cash flow is projected. The company's strategic priorities include a displacement campaign for the eValuator tool, strengthening the Oracle (NYSE:ORCL ) partnership, developing new channel partnerships, and maximizing upsells and cross-sells within the existing client base.
InvestingPro Insights


Streamline Health Solutions Inc. (NASDAQ:STRM) has seen notable activity from its President and CEO, Benjamin Louis Stilwill, underscoring a potential confidence in the company's trajectory. While insider transactions can often signal corporate health and direction, understanding the broader financial context is crucial for investors. Here are some recent data points and analysis from InvestingPro that provide a deeper look into Streamline Health Solutions' financial status:
The company's market capitalization stands at a modest $10.25 million, suggesting it is a micro-cap stock which typically entails higher risk and volatility.
With a negative P/E ratio of -0.52 for the last twelve months as of Q2 2025, Streamline Health Solutions is not currently profitable, which aligns with the InvestingPro Tip that analysts do not anticipate the company will be profitable this year.
Revenue has declined by 15.64% over the same period, reinforcing concerns from an InvestingPro Tip about an anticipated sales decline in the current year.


InvestingPro Tips further reveal that Streamline Health Solutions operates with a significant debt burden and is quickly burning through cash. Additionally, the stock is considered to be in oversold territory according to the Relative Strength Index (RSI), which could be of interest to investors looking for potential buying opportunities. However, the stock's price has experienced a substantial drop over the past year, which may raise questions about its short-term performance prospects.

For those interested in a comprehensive analysis, InvestingPro offers 13 additional tips on Streamline Health Solutions Inc., which can be accessed at InvestingPro. These insights may help investors gauge the potential risks and rewards associated with the company's stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com